Fig. 1: Brief representation of COReNAPCIN® design, production, and evaluation. | npj Vaccines

Fig. 1: Brief representation of COReNAPCIN® design, production, and evaluation.

From: SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN®, induces robust humoral and cellular immunity in mice and non-human primates

Fig. 1

a Structure of COReNAPCIN® mRNA. b Structure of COReNAPCIN® mRNA encoded SARS-CoV-2 Spike glycoprotein-2P. The 2 P abbreviation indicates substitution of native amino acids with two proline residues at positions 986 and 987 to produce the pre-fusion stabilized form of the Spike glycoprotein for better antigenic representation at the cell surface. c Evaluation of the purity and integrity of the produced COReNAPCIN® mRNA with gel electrophoresis. d Schematic representation of COReNAPCIN® production procedure. The COReNAPCIN® mRNA is made by in-vitro transcription (IVT) from the linearized plasmid DNA template, then is mixed with special lipid components to form the final COReNAPCIN® mRNA-LNP drug product. e Evaluation of the size distribution of COReNAPCIN® mRNA-LNPs with Dynamic Light Scattering (DLS). f Evaluation of the COReNAPCIN® particles by Transmission Electron Microscopy (TEM). g Evaluation of mRNA encapsulation efficiency by Gel Retardation Assay. h Evaluation of the expression of SARS-CoV-2 Spike glycoprotein-2P at the cell surface by flow cytometry. i Evaluation of SARS-CoV-2 Spike glycoprotein-2P expression by Western Blotting.

Back to article page